Ovid Therapeutics Inc. Files Definitive Proxy Statement

TL;DR

<b>Ovid Therapeutics Inc. has filed its Definitive Proxy Statement for the 2024 Annual Meeting.</b>

AI Summary

Ovid Therapeutics Inc. (OVID) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Ovid Therapeutics Inc. filed a Definitive Proxy Statement (DEF 14A) on April 24, 2024. The filing is for the fiscal year ending December 31, 2023. The company's principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, NY 10001. The filing fee was not required. The company is incorporated in Delaware.

Why It Matters

For investors and stakeholders tracking Ovid Therapeutics Inc., this filing contains several important signals. This filing provides shareholders with essential information regarding the upcoming 2024 Annual Meeting, including details on voting procedures and matters to be discussed. As a DEF 14A filing, it signifies the final version of the proxy materials being sent to shareholders, indicating the company is proceeding with its annual meeting and related corporate governance activities.

Risk Assessment

Risk Level: low — Ovid Therapeutics Inc. shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate governance procedures rather than significant new developments or financial events.

Analyst Insight

Shareholders should review the proxy statement to understand the proposals being voted on and to cast their votes for the 2024 Annual Meeting.

Key Numbers

• 2024-04-24 — Filing Date (DEF 14A Filing Date)
• 1231 — Fiscal Year End (Ovid Therapeutics Inc. Fiscal Year End)
• 2834 — SIC Code (Ovid Therapeutics Inc. Standard Industrial Classification)
• 001-38085 — SEC File Number (Ovid Therapeutics Inc. SEC File Number)
• 24871330 — Film Number (Ovid Therapeutics Inc. Film Number)

Key Players & Entities

• Ovid Therapeutics Inc. (company) — Registrant
• 441 Ninth Avenue, 14th Floor (location) — Business Address
• New York (location) — Business Address City
• NY (location) — Business Address State
• 10001 (location) — Business Address Zip
• 212-776-4381 (phone) — Business Phone
• DE (location) — State of Incorporation
• 2024-04-24 (date) — Filing Date

FAQ

Industry Context

Ovid Therapeutics Inc. operates in the Pharmaceutical Preparations industry, focusing on the development of novel medicines.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

What Investors Should Do

1. Review the full DEF 14A filing for details on proposals and voting.
2. Note the company's principal business address and contact information.
3. Confirm the fiscal year end and SIC code for industry classification.

Key Dates

• 2024-04-24: Filing of Definitive Proxy Statement (DEF 14A) — Indicates the final proxy materials are being distributed to shareholders for the upcoming annual meeting.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure, and does not inherently indicate changes from previous filings without comparative data.

Filing Documents

• ovid-20240424.htm (DEF 14A) — 856KB
• img44212337_0.jpg (GRAPHIC) — 237KB
• img44212337_1.jpg (GRAPHIC) — 16KB
• img44212337_2.jpg (GRAPHIC) — 90KB
• img44212337_3.jpg (GRAPHIC) — 85KB
• img44212337_4.jpg (GRAPHIC) — 87KB
• img44212337_5.jpg (GRAPHIC) — 21KB
• img44212337_6.jpg (GRAPHIC) — 21KB
• img44212337_7.jpg (GRAPHIC) — 904KB
• img44212337_8.jpg (GRAPHIC) — 750KB
• 0000950170-24-047673.txt (&nbsp;) — 6467KB
• ovid-20240424.xsd (EX-101.SCH) — 29KB
• ovid-20240424_htm.xml (XML) — 117KB

(V) PAY VERSUS PERFORMANCE

ITEM 402(V) PAY VERSUS PERFORMANCE 31 EQUITY COMPENSATION PLAN INFORMATION 34 TRANSACTIONS WITH RELATED PERSONS 35 Policies and Procedures Regarding Transactions with Related Parties 35 Certain Related-Party Transactions 35 Indemnification Agreements 35

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 36 DELINQUENT SECTION 16(A) REPORTS 39 HOUSEHOLDING OF PROXY MATERIALS 40 OTHER MATTERS 41 Website References You may also access additional information about Ovid Therapeutics, Inc. at www.ovidrx.com and investors.ovidrx.com . References to our websites throughout this proxy statement are provided for convenience only and the content on our website does not constitute a part of this proxy statement. i OVID THERAPEUTICS INC. 441 Ninth Avenue, 14 th Floor New York, New York 10001 (646) 661-7661 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 6, 2024 AT 10:00 A.M. EASTERN TIME QUESTIONS AND ANSWERS ABOUT THE SE PROXY MATERIALS AND VOTING Why did I receive a Notice of Internet Availability of Proxy Materials (" Notice ") on the Internet instead of a full set of Proxy Materials? Pursuant to rules adopted by the Securities and Exchange Commission (the " SEC "), we have elected to provide access to our Proxy Materials over the Internet. Accordingly, we have sent you a Notice because the Board of Directors of Ovid Therapeutics Inc. (the " Board ") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the " Annual Meeting ") of Ovid Therapeutics Inc. This proxy statement and proxy card or, for shares held in street name (held for your account by a broker or other nominee), voting instruction form, and the Annual Report on Form 10-K for the year ended December 31, 2023 (collectively the " Proxy Materials ") are available to stockholders on the internet. Instructions on how to access the Proxy Materials over the internet or instructions on how to request a printed copy of the Proxy Materials may be found in the Notice. The Notice will also provide instructions as to how a stockholder of record may access and review the Proxy Materials, on the website referred to in the Notice or, alternatively, how to request that a c